Genetic landscape of hereditary cardiomyopathies and arrhythmias in China

Yang Lu; Zeyuan Wang; Shuyuan Zhang; Yaping Liu; Ye Jin; Zhuang Tian; Shuyang Zhang

doi:10.1016/j.jgg.2025.07.003

Genetic landscape of hereditary cardiomyopathies and arrhythmias in China

doi: 10.1016/j.jgg.2025.07.003

a. Department of Cardiology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;
b. Medical Center for Rare Diseases, State Key Laboratory for Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing 100730, China;
c. Center for Digital Medicine and Artificial Intelligence, National Infrastructures for Translational Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;
d. International Medical Service, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

基金项目:

This work was supported by Science, Technology &

Innovation Project of Xiongan New Area (2023XAGG0069), National Key Research and Development Program of China (2022YFC2703100), National High Level Hospital Clinical Research Funding (2022-PUMCH-D-002), the National Natural Science Foundation of China (824B2011 to Z.W.), and National High Level Hospital Clinical Research Funding (2023-PUMCH-E-012).

详细信息

通讯作者:
Ye Jin,E-mail:jinye0320@163.com

Zhuang Tian,E-mail:tianzhuangcn@sina.com

Shuyang Zhang,E-mail:shuyangzhang103@163.com

计量
- 文章访问数: 15
- HTML全文浏览量: 6
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2025-03-14
- 录用日期: 2025-07-05
- 修回日期: 2025-07-04
- 刊出日期: 2026-02-10

Genetic landscape of hereditary cardiomyopathies and arrhythmias in China

Yang Lu^a,
Zeyuan Wang^a,
Shuyuan Zhang^a,
Yaping Liu^b,
Ye Jin^{b,c
, ,},
Zhuang Tian^{a,d
, ,},
Shuyang Zhang^{a,b
, ,}

a. Department of Cardiology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;
b. Medical Center for Rare Diseases, State Key Laboratory for Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing 100730, China;
c. Center for Digital Medicine and Artificial Intelligence, National Infrastructures for Translational Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;
d. International Medical Service, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds:

This work was supported by Science, Technology &

摘要

摘要: Hereditary cardiomyopathies and arrhythmias are major contributors to cardiovascular morbidity and mortality. The advent of next-generation sequencing (NGS) has made genetic testing more accessible, which is crucial for precise diagnosis and targeted therapeutic strategies. The aim of this study is to explore the landscape of genetic variants, the relationship between specific variants and clinical phenotypes, and the impact on clinical decision-making in China. A total of 1536 probands (median age, 37 years; 1025 males [66.7%]) with suspected hereditary cardiomyopathy or arrhythmia (covering 15 clinical phenotypes) are recruited from 146 hospitals across 30 provinces and cities in China. Positive results are confirmed in 390 of 1536 probands, leading to a diagnostic yield of 25.4%. Forty-two and three-tenths percent (n = 169) of family members carry the same variants as positive probands. Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) are the predominant phenotypes, with MYBPC3 variants having the highest frequency in HCM and TTN variants in DCM. In 76.9% of the positive probands, the identified variants are helpful in clinical management, family screening, and fertility. This large-scale study provides significant insights into the genetic landscape of hereditary cardiomyopathies and arrhythmias in China.
- Genetic testing /
- Cardiomyopathy /
- Arrhythmia /
- Diagnostic yield /
- Chinese population /
- Cardiovascular genetics
Abstract: Hereditary cardiomyopathies and arrhythmias are major contributors to cardiovascular morbidity and mortality. The advent of next-generation sequencing (NGS) has made genetic testing more accessible, which is crucial for precise diagnosis and targeted therapeutic strategies. The aim of this study is to explore the landscape of genetic variants, the relationship between specific variants and clinical phenotypes, and the impact on clinical decision-making in China. A total of 1536 probands (median age, 37 years; 1025 males [66.7%]) with suspected hereditary cardiomyopathy or arrhythmia (covering 15 clinical phenotypes) are recruited from 146 hospitals across 30 provinces and cities in China. Positive results are confirmed in 390 of 1536 probands, leading to a diagnostic yield of 25.4%. Forty-two and three-tenths percent (n = 169) of family members carry the same variants as positive probands. Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) are the predominant phenotypes, with MYBPC3 variants having the highest frequency in HCM and TTN variants in DCM. In 76.9% of the positive probands, the identified variants are helpful in clinical management, family screening, and fertility. This large-scale study provides significant insights into the genetic landscape of hereditary cardiomyopathies and arrhythmias in China.
- Genetic testing /
- Cardiomyopathy /
- Arrhythmia /
- Diagnostic yield /
- Chinese population /
- Cardiovascular genetics

HTML全文

参考文献(52)

Ader, F., Jedraszak, G., Janin, A., Billon, C., Buisson, N.R., Bloch, A., Bensalah, M., De Sandre-Giovannoli, A., Goudal, A., Marsili, L., et al., 2024. Prevalence and phenotypes associated with ALPK3 null variants in a large French multicentric cohort: confirming its involvement in hypertrophic cardiomyopathy. Clin. Genet. 105, 676-682.

Amr, A., Koelemen, J., Reich, C., Sedaghat-Hamedani, F., Kayvanpour, E., Haas, J., Frese, K., Lehmann, D., Katus, H.A., Frey, N., et al., 2023. Improving sudden cardiac death risk stratification in hypertrophic cardiomyopathy using established clinical variables and genetic information. Clinical Research in Cardiology 113, 728-736.

Anastasiou, V., Papazoglou, A.S., Gossios, T., Zegkos, T., Daios, S., Moysidis, D.V., Koutsiouroumpa, O., Parcharidou, D., Tziomalos, G., Katranas, S., et al., 2024. Prognostic implications of genotype findings in non-ischaemic dilated cardiomyopathy: a network meta-analysis. Eur. J. Heart Fail. 26, 2155-2168.

Antoku, S., Schwartz, T.U., Gundersen, G.G., 2023. FHODs: nuclear tethered formins for nuclear mechanotransduction. Front. Cell Dev. Biol. 11, 1160219.

Arbelo, E., Protonotarios, A., Gimeno, J.R., Arbustini, E., Barriales-Villa, R., Basso, C., Bezzina, C.R., Biagini, E., Blom, N.A., de Boer, R.A., et al., 2023. 2023 ESC guidelines for the management of cardiomyopathies. Eur. Heart J. 44, 3503-3626.

Bottillo, I., Giordano, C., Ciccone, M.P., Pignataro, M.G., Albi, F., Parisi, G., Formicola, D., Grotta, S., Ranocchi, F., Giuli, M.V., et al., 2024. Dilated cardiomyopathy due to a novel combination of TTN and BAG3 genetic variants: from acute heart failure to subclinical phenotypes. Cardiovasc. Pathol. 73, 107675.

Cao, Y., Li, L., Xu, M., Feng, Z., Sun, X., Lu, J., Xu, Y., Du, P., Wang, T., Hu, R., et al., 2020. The ChinaMAP analytics of deep whole genome sequences in 10,588 individuals. Cell Res. 30, 717-731.

Chen, Q., Hong, D., Huang, Y., Zhang, Z., Wang, S., 2024. Phenotypic and genotypic spectrum of noonan syndrome: a retrospective analysis of 46 consecutive pediatric patients presented at a regional cardiac center in China. Heliyon 10, e27038.

Conway, K.M., Thomas, S., Neyaz, T., Ciafaloni, E., Mann, J.R., Staron-Ehlinger, M., Beasley, G.S., Romitti, P.A., Mathews, K.D., 2025. Prophylactic use of cardiac medications and survival in duchenne muscular dystrophy. Muscle Nerve 71, 574-582.

Dai, J., Li, K., Huang, M., Sun, Y., Liu, H., Li, Z., Chen, P., Wang, H., Wu, D., Chen, Y., et al., 2022. The involvement of ALPK3 in hypertrophic cardiomyopathy in East Asia. Front. Med. (Lausanne) 9, 915649.

Dellefave-Castillo, L.M., Cirino, A.L., Callis, T.E., Esplin, E.D., Garcia, J., Hatchell, K.E., Johnson, B., Morales, A., Regalado, E., Rojahn, S., et al., 2022. Assessment of the diagnostic yield of combined cardiomyopathy and arrhythmia genetic testing. JAMA Cardiology 7, 966-974.

El Naofal, M., Ramaswamy, S., Alsarhan, A., Nugud, A., Sarfraz, F., Janbaz, H., Taylor, A., Jain, R., Halabi, N., Yaslam, S., et al., 2023. The genomic landscape of rare disorders in the Middle East. Genome Medicine 15, 5.

Escobar-Lopez, L., Ochoa, J.P., Mirelis, J.G., Espinosa, M.A., Navarro, M., Gallego-Delgado, M., Barriales-Villa, R., Robles-Mezcua, A., Basurte-Elorz, M.T., Gutierrez Garcia-Moreno, L., et al., 2021. Association of genetic variants with outcomes in patients with nonischemic dilated cardiomyopathy. J. Am. Coll. Cardiol. 78, 1682-1699.

Fontana, M., Solomon, S.D., Kachadourian, J., Walsh, L., Rocha, R., Lebwohl, D., Smith, D., Taubel, J., Gane, E.J., Pilebro, B., et al., 2024. CRISPR-Cas9 gene editing with nexiguran ziclumeran for ATTR cardiomyopathy. N. Engl. J. Med. 391, 2231-2241.

Garcia-Pavia, P., Kim, Y., Restrepo-Cordoba, M.A., Lunde, I.G., Wakimoto, H., Smith, A.M., Toepfer, C.N., Getz, K., Gorham, J., Patel, P., et al., 2019. Genetic variants associated with cancer therapy-induced cardiomyopathy. Circulation 140, 31-41.

Gillmore, J.D., Judge, D.P., Cappelli, F., Fontana, M., Garcia-Pavia, P., Gibbs, S., Grogan, M., Hanna, M., Hoffman, J., Masri, A., et al., 2024. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 390, 132-142.

Greenberg, B., Taylor, M., Adler, E., Colan, S., Ricks, D., Yarabe, P., Battiprolu, P., Shah, G., Patel, K., Coggins, M., et al., 2024. Phase 1 study of AAV9.LAMP2B gene therapy in Danon disease. N. Engl. J. Med. 392, 972-983.

Greer-Short, A., Greenwood, A., Leon, E.C., Qureshi, T.N., von Kraut, K., Wong, J., Tsui, J.H., Reid, C.A., Cheng, Z., Easter, E., et al., 2025. AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models. Nat. Commun. 16, 2196.

Herkert, J.C., Verhagen, J.M.A., Yotti, R., Haghighi, A., Phelan, D.G., James, P.A., Brown, N.J., Stutterd, C., Macciocca, I., Leong, K., et al., 2020. Expanding the clinical and genetic spectrum of ALPK3 variants: phenotypes identified in pediatric cardiomyopathy patients and adults with heterozygous variants. Am. Heart J. 225, 108-119.

Herman, D.S., Lam, L., Taylor, M.R., Wang, L., Teekakirikul, P., Christodoulou, D., Conner, L., DePalma, S.R., McDonough, B., Sparks, E., et al., 2012. Truncations of titin causing dilated cardiomyopathy. N. Engl. J. Med. 366, 619-628.

Iskratsch, T., Reijntjes, S., Dwyer, J., Toselli, P., Degano, I.R., Dominguez, I., Ehler, E., 2013. Two distinct phosphorylation events govern the function of muscle FHOD3. Cell Mol. Life Sci. 70, 893-908.

Jansen, M., de Brouwer, R., Hassanzada, F., Schoemaker, A.E., Schmidt, A.F., Kooijman-Reumerman, M.D., Bracun, V., Slieker, M.G., Dooijes, D., Vermeer, A.M.C., et al., 2024. Penetrance and prognosis of MYH7 variant-associated cardiomyopathies: results from a Dutch multicenter cohort study. JACC Heart Fail. 12, 134-147.

Jensen, M.K., Havndrup, O., Christiansen, M., Andersen, P.S., Diness, B., Axelsson, A., Skovby, F., Kober, L., Bundgaard, H., 2013. Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing. Circulation 127, 48-54.

Lahrouchi, N., Tadros, R., Crotti, L., Mizusawa, Y., Postema, P.G., Beekman, L., Walsh, R., Hasegawa, K., Barc, J., Ernsting, M., et al., 2020. Transethnic genome-wide association study provides insights in the genetic architecture and heritability of long QT syndrome. Circulation 142, 324-338.

Leinhos, L., Robinson, P., Poloni, G., Broadway-Stringer, S., Beglov, J., Lokman, A.B., Douglas, G., Nuthay, S., Fonseka, O., Schmid, M., et al., 2025. An ALPK3 truncation variant causing autosomal dominant hypertrophic cardiomyopathy is partially rescued by mavacamten. Sci. Rep. 15, 10090.

Marian, A.J., Asatryan, B., Wehrens, X.H.T., 2020. Genetic basis and molecular biology of cardiac arrhythmias in cardiomyopathies. Cardiovasc. Res. 116, 1600-1619.

Maron, B.J., Roberts, W.C., Arad, M., Haas, T.S., Spirito, P., Wright, G.B., Almquist, A.K., Baffa, J.M., Saul, J.P., Ho, C.Y., et al., 2009. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA 301, 1253-1259.

Maron, B.J., Spirito, P., Roman, M.J., Paranicas, M., Okin, P.M., Best, L.G., Lee, E.T., Devereux, R.B., 2004. Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study). Am. J. Cardiol. 93, 1510-1514.

Maurer, M.S., Schwartz, J.H., Gundapaneni, B., Elliott, P.M., Merlini, G., Waddington-Cruz, M., Kristen, A.V., Grogan, M., Witteles, R., Damy, T., et al., 2018. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 379, 1007-1016.

McKenna, W.J., Judge, D.P., 2021. Epidemiology of the inherited cardiomyopathies. Nat. Rev. Cardiol. 18, 22-36.

Moss, A.J., Shimizu, W., Wilde, A.A., Towbin, J.A., Zareba, W., Robinson, J.L., Qi, M., Vincent, G.M., Ackerman, M.J., Kaufman, E.S., et al., 2007. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation 115, 2481-2489.

Ochoa, J.P., Sabater-Molina, M., Garcia-Pinilla, J.M., Mogensen, J., Restrepo-Cordoba, A., Palomino-Doza, J., Villacorta, E., Martinez-Moreno, M., Ramos-Maqueda, J., Zorio, E., et al., 2018. Formin homology 2 domain containing 3 (FHOD3) is a genetic basis for hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 72, 2457-2467.

Ommen, S.R., Ho, C.Y., Asif, I.M., Balaji, S., Burke, M.A., Day, S.M., Dearani, J.A., Epps, K.C., Evanovich, L., Ferrari, V.A., et al., 2024. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines. Circulation. 149, e1239-e1311.

Pieroni, M., Moon, J.C., Arbustini, E., Barriales-Villa, R., Camporeale, A., Vujkovac, A.C., Elliott, P.M., Hagege, A., Kuusisto, J., Linhart, A., et al., 2021. Cardiac involvement in Fabry disease: JACC review topic of the week. J. Am. Coll. Cardiol. 77, 922-936.

Politano, L., 2024. Is cardiac transplantation still a contraindication in patients with muscular dystrophy-related end-stage dilated cardiomyopathy? a systematic review. Int. J. Mol. Sci. 25, 5289.

Protonotarios, A., Bariani, R., Cappelletto, C., Pavlou, M., Garcia-Garcia, A., Cipriani, A., Protonotarios, I., Rivas, A., Wittenberg, R., Graziosi, M., et al., 2022. Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator. Eur. Heart. J. 43, 3053-3067.

Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W.W., Hegde, M., Lyon, E., Spector, E., et al., 2015. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405-424.

Sambri, I., Ferniani, M., Campostrini, G., Testa, M., Meraviglia, V., de Araujo, M. E. G., Dokladal, L., Vilardo, C., Monfregola, J., Zampelli, N., et al., 2023. RagD auto-activating mutations impair MiT/TFE activity in kidney tubulopathy and cardiomyopathy syndrome. Nat. Commun. 14, 2775.

Schlingmann, K.P., Jouret, F., Shen, K., Nigam, A., Arjona, F.J., Dafinger, C., Houillier, P., Jones, D.P., Kleineruschkamp, F., Oh, J., et al., 2021. mTOR-activating mutations in RRAGD are causative for kidney tubulopathy and cardiomyopathy. J. Am. Soc. Nephrol. 32, 2885-2899.

Song, D., Dai, Y., Chen, X., Fu, X., Chang, X., Wang, N., Zhang, C., Yan, C., Zheng, H., Wu, L., et al., 2021. Genetic variations and clinical spectrum of dystroglycanopathy in a large cohort of Chinese patients. Clin. Genet. 99, 384-395.

Sun, J., Han, S., Hu, J., Jiang, C., Wang, Q., Zheng, L., Zhou, Z., Qi, M., 2020. Clinical practice guidelines for hereditary cardiomyopathy. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 37, 300-307.

Tadros, R., Francis, C., Xu, X., Vermeer, A.M.C., Harper, A.R., Huurman, R., Kelu Bisabu, K., Walsh, R., Hoorntje, E.T., Te Rijdt, W.P., et al., 2021. Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nat. Genet. 53, 128-134.

Tavtigian, S.V., Harrison, S.M., Boucher, K.M., Biesecker, L.G., 2020. Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelines. Hum. Mutat. 41, 1734-1737.

Towbin, J.A., McKenna, W.J., Abrams, D.J., Ackerman, M.J., Calkins, H., Darrieux, F.C.C., Daubert, J.P., de Chillou, C., DePasquale, E.C., Desai, M.Y., et al., 2019. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm 16, e301-e372.

Trepiccione, F., Sambri, I., Ruggiero, B., Emma, F., Ballabio, A., Florio, G., Vanderheyden, I., Iervolino, A., Jouret, F., 2024. RRAGD-associated autosomal dominant kidney hypomagnesemia with cardiomyopathy: a review on the clinical manifestations and therapeutic options. Kidney Blood Press. Res. 49, 637-645.

Villard, E., Perret, C., Gary, F., Proust, C., Dilanian, G., Hengstenberg, C., Ruppert, V., Arbustini, E., Wichter, T., Germain, M., et al., 2011. A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur. Heart. J. 32, 1065-1076.

Wang, Y., Starovoytov, A., Murad, A.M., Hunker, K.L., Brunham, L.R., Li, J.Z., Saw, J., Ganesh, S.K., 2022. Burden of rare genetic variants in spontaneous coronary artery dissection with high-risk features. JAMA Cardiology 7, 1045-1055.

Ware, J.S., Amor-Salamanca, A., Tayal, U., Govind, R., Serrano, I., Salazar-Mendiguchia, J., Garcia-Pinilla, J.M., Pascual-Figal, D.A., Nunez, J., Guzzo-Merello, G., et al., 2018. Genetic etiology for alcohol-induced cardiac toxicity. J. Am. Coll. Cardiol. 71, 2293-2302.

Wilde, A.A.M., Semsarian, C., Marquez, M.F., Sepehri Shamloo, A., Ackerman, M.J., Ashley, E.A., Sternick, E.B., Barajas-Martinez, H., Behr, E.R., Bezzina, C.R., et al., 2022. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus statement on the state of genetic testing for cardiac diseases. Heart Rhythm 19, e1-e60.

Wojcik, M.H., Lemire, G., Berger, E., Zaki, M.S., Wissmann, M., Win, W., White, S.M., Weisburd, B., Wieczorek, D., Waddell, L.B., et al., 2024. Genome sequencing for diagnosing rare diseases. N. Engl. J. Med. 390, 1985-1997.

Zhang, Q., Chan, W., Chen, Y., Wu, J., Chen, H., Yu, T., Yao, R., Chen, L., Zhang, B., Zhang, H., et al., 2024. Clinical and genetic profile of Chinese children with Danon disease: a single-center retrospective cohort study. Can. J. Cardiol. 41, 89-101.

Zhou, N., Weng, H., Zhao, W., Tang, L., Ge, Z., Tian, F., Meng, F., Pan, C., Shu, X., 2023. Gene-echocardiography: refining genotype-phenotype correlations in hypertrophic cardiomyopathy. Eur. Heart J. Cardiovasc. Imaging 25, 127-135.

施引文献

资源附件(0)

访问统计